Edition:
United States

Zhejiang Huahai Pharmaceutical Co Ltd (600521.SS)

600521.SS on Shanghai Stock Exchange

19.42CNY
2:59am EDT
Change (% chg)

¥-1.42 (-6.81%)
Prev Close
¥20.84
Open
¥20.76
Day's High
¥21.05
Day's Low
¥19.20
Volume
16,549,644
Avg. Vol
13,451,996
52-wk High
¥32.83
52-wk Low
¥16.02

Chart for

About

ZHEJIANGHUAHAIPHARMACEUTICALCO., LTD is a China-based company, principally engaged in the manufacture and distribution of active pharmaceutical ingredients (APIs), intermediates and preparations. The Company's main products are classified as -pril series, -sartan series and preparations, including irbesartan tablets, paroxetine... (more)

Overall

Beta: 0.58
Market Cap(Mil.): ¥26,067.48
Shares Outstanding(Mil.): 1,250.84
Dividend: 0.17
Yield (%): 0.80

Financials

  600521.SS Industry Sector
P/E (TTM): 39.50 28.11 30.17
EPS (TTM): 0.53 -- --
ROI: 12.49 12.95 12.67
ROE: 13.80 14.96 14.86

India’s Hetero pulls heart drug from U.S. amid cancer risk probes

MUMBAI A unit of India’s Hetero Drugs is recalling some batches of the blood pressure and heart medicine valsartan in the United States, a notice on the U.S. regulator's website said, amid a wider probe into cancer risks associated with the drug.

Aug 11 2018

India’s Hetero pulls heart drug from U.S. amid cancer risk probes

MUMBAI, Aug 11 A unit of India’s Hetero Drugs is recalling some batches of the blood pressure and heart medicine valsartan in the United States, a notice on the U.S. regulator's website said, amid a wider probe into cancer risks associated with the drug.

Aug 11 2018

EU says second China company made tainted heart drug

FRANKFURT The European Medicines Agency (EMA) said on Friday that a second Chinese contract manufacturer, Zhejiang Tianyu, had produced a common blood pressure and heart drug with an impurity that could cause cancer.

Aug 10 2018

EU says second China company made tainted heart drug

FRANKFURT, Aug 10 The European Medicines Agency (EMA) said on Friday that a second Chinese contract manufacturer, Zhejiang Tianyu, had produced a common blood pressure and heart drug with an impurity that could cause cancer.

Aug 10 2018

China tells medical institutions to stop using Huahai heart drug

SHANGHAI China's health regulator has ordered local medical institutions to stop using a heart drug from Zhejiang Huahai Pharmaceutical Co Ltd, in a directive that comes just days after another case of a tainted medical product.

Jul 30 2018

UPDATE 3-China tells medical institutions to stop using Huahai heart drug

* Chinese drugmaker stocks trade lower (Recasts; adds analyst comment)

Jul 30 2018

China orders medical institutions not to use recalled valsartan drug

SHANGHAI, July 30 China's health regulator has called on all medical institutions to cooperate with authorities and not use the valsartan blood and heart drug that is said to pose cancer risks.

Jul 29 2018

Earnings vs. Estimates